DOCSLIB.ORG

GBL) in a Primary Care Clinic J Am Board Fam Pract: First Published As on 1 March 2002

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GBL) in a Primary Care Clinic J Am Board Fam Pract: First Published As on 1 March 2002 Treatment of a Young Adult Taking Gamma- Butyrolactone (GBL) in a Primary Care Clinic J Am Board Fam Pract: first published as on 1 March 2002. Downloaded from Arthur H. Herold, MD, and Kevin B. Sneed, PharmD Gamma-butyrolactone (GBL) has become the new withdrawn from its use. The patient had begun drug of choice for young adults to abuse.1–4 The using GHB then GBL recreationally 4 years ear- effects it induces include euphoria,disinhibition, lier,after learning about it from his college and depressed levels of consciousness,and eventual re- gym acquaintances. He reported that GHB and spiratory depression.5 GBL is metabolized into GBL were widely available,and their use was per- gamma-hydroxybutyrate (GHB),which is also a vasive in those two settings. In addition to produc- recreational drug and is now a schedule I drug in ing euphoria,GBL helped with his insomnia. He some states.5,6 Both GBL and GHB are used in did not use tobacco products or alcohol,and he had social settings similar to those where ecstasy (meth- no history of cocaine,marijuana,narcotics,or pre- ylenedioxymethamphetamine,or MDMA) is used, scription drug abuse. When he had first started although GBL and GHB are chemically distinct using GHB and GBL,he also had experimented from ecstasy.7 briefly with ectasy and anabolic steroids. Recent reports have been published describing His use of GBL increased so that at time of his toxic effects of GBL that lead to emergency depart- visit he was taking 1 oz every 2 hours. Attempts to ment visits and death.3 The overall prevalence of discontinue use would aggravate his insomnia and GBL use in America is unknown,although it is cause craving,dysphoria,sweating,generalized suspected to be high because the drug is available tremors,and palpitations,but he reported no ab- through underground sources. GBL is also readily dominal pain,nausea,vomiting,diarrhea,shortness available from Internet sources,where it is touted of breath,or chest pain. When examined,he was a for its ability to induce sleep,enhance libido and well-developed muscular man,5 feet 9 inches tall, http://www.jabfm.org/ sexual performance,and increase lean muscle who weighed 240 pounds. His temperature,blood mass.8,9 Despite numerous warnings about the pressure,respirations,and heart rate were normal, harmful side effects,young adults who continue to and he had a slightly depressed mood. Laboratory use this drug can experience physical and psycho- studies,including a complete blood count,lipid logical addictions,as well as acute altered mental profile,chemistry profile,thyroid function test,and status and severe respiratory depression. The wide- urinalysis,were all normal. on 1 October 2021 by guest. Protected copyright. spread use of GBL suggests that primary care phy- The patient agreed to be withdrawn from the sicians should become more aware of its potential GBL if prescription medications could be used to adverse effects and develop modes of treatment for ameliorate his symptoms. Clonidine,0.1 mg three drug-using patients who attend their clinics. We times a day,was prescribed,which lessened his report a case of a young man seeking medical care craving and dysphoria. Two weeks later,however, because of GBL addiction. he complained of continued sweating,tremors,and palpitations; these symptoms responded to pro- Case Report pranolol,20 mg three times a day. Because his insomnia did not respond first to amitriptyline,25 A 27-year-old male body builder in good health mg,or zaleplon,5 mg,the patient continued using came to the family medicine clinic with the chief 1.5 oz of the GBL at bedtime. Seven of his nine complaint of addiction to GBL and a desire to be depressive symptoms had responded positively,and paroxetine,30 mg,was prescribed. Although his mood,self-image,and energy level improved after Submitted,revised 31 October 2001. From the Department of Family Medicine (AHH,KBS), 4 weeks of treatment,his insomnia persisted. Di- University of South Florida,Tampa. Address reprint re- azepam,5 mg,at bedtime was added,which al- quests to Kevin B. Sneed,PharmD,Department of Family Medicine,University of South Florida,12901 Bruce B. lowed the patient to taper off the remaining 1.5 oz Downs Blvd,MDC13,Tampa,Fl 33612. of GBL. Gamma-Butyrolactone (GBL) 161 Discussion Although acute ingestion of GBL might lead to Although this patient sought medical care,clini- sedation,chronic recreational use can lead to a 9,13 J Am Board Fam Pract: first published as on 1 March 2002. Downloaded from cians should inquire about GBL or GHB use in number of neurologic problems. Withdrawing patients from this illicit drug can be a challenge for high-risk populations and in those who complain of the family physician. Successful treatment in our possible symptoms of withdrawal. GBL is the pre- patient required a combination of medications that cursor to GHB,a schedule I drug. GBL can be act on various central and peripheral receptors. obtained easily from Internet sources,an avenue by The action of clonidine on the central ␣-adrenergic which our patient obtained it. The scientific name receptors,inhibition of serotonin uptake by parox- of GBL is 2(3H) dihydro furanone,and it is me- etine,and peripheral ␤-adrenergic receptor block- tabolized into 4-hydroxybutyrate (GHB). GHB is a ade by propranolol were all required to reduce our ␥ naturally occurring fatty-acid derivative of -ami- patient’s withdrawal symptoms. We chose oral ad- 10 nobutyric acid (GABA). It is believed to have ministration for clonidine because of its ease of inhibitory effects on GABA receptors in the central titration and cost convenience,although topical nervous system,producing sedating effects. Insom- clonidine might have been an overall more effective nia was the reason that our patient gave for begin- method for withdrawal treatment. Stimulation of ning his drug use. Dopamine synthesis is increased the GABA receptors by diazepam was necessary, in GHB and GBL users,probably as a result of however,for complete cessation of use. This use of tyrosine hydroxylase stimulation,the enzyme in- a benzodiazepine is consistent with reported treat- volved in the initial steps of dopamine synthesis. ment of GHB withdrawal cited in the litera- Acute ingestion can cause symptoms of central ture.14,15 Our patient’s chronic GBL use might nervous system depression,respiratory depression, have produced central GABA depletion with result- bradycardia,and involuntary movements,requiring ant increased insomnia when GBL was discontin- emergency management.6,11 Chronic use of these ued. Insomnia was the symptom he found to be the drugs can lead to several neurotoxic effects,includ- most objectionable. ing anxiety,depression,tremor,and insomnia,all Given the current availability and use of GBL of which were reported in our case. An example of and GHB,clinicians must have a heightened http://www.jabfm.org/ the effects of physical dependence,Wernicke-Kor- awareness of the use of these drugs among certain sakoff syndrome,has been reported in a chronic patients. A combination of medications might be user.12 Despite the increased possibilities of these required to help the patient successfully withdraw adverse events,the ability of GHB and GBL to from use. Because of the effects of GBL on critical induce a euphoric state has made these drugs a neurotransmitters responsible for emotions and reasoning,physicians should be aware of the po- favorite among young adults on the party scene. on 1 October 2021 by guest. Protected copyright. tential for sustained anxiety,depression,and possi- GBL is marketed for its many positive effects on bly even suicidal tendencies. With these possibili- the users,including its ability to (1) induce deep ties in mind,physicians should refer patients for sleep,(2) treat neurologic disorders (fibromyalgia), follow-up in a drug treatment program,where their (3) increase lean muscle tissue,(4) decrease fat psychosocial activities can receive additional atten- tissue,(5) enhance libido and sexual performance, tion,and they can be helped with continued cessa- (6) eliminate hair loss,and (7) stimulate growth tion of these recreational drugs. hormones. A search on the Internet using a default search engine recovered various Web links to sites References promoting the sale of GBL and GHB-like alterna- 1. Kam PC,Yoong FF. Gamma-hydroxybutyric acid: 8,9 tives. These products are sought out by body- an emerging recreational drug. Anaesthesia 1998;53: builders,and a sizable underground market exists in 1195–8. this population. Young adult partygoers use GBL 2. Smith KM. Drug used in acquaintance rape. J Am at rave parties; it is colorless,odorless,and almost Pharm Assoc (Wash) 1999;39:519–25. tasteless when mixed with fluids. Because it is ac- 3. Viera AJ,Yates SW. Toxic ingestion of gamma- hydroxybutyric acid. South Med J 1999;92:404–5. cessible and easy to consume,both by the aware 4. Li J. The new “Mickey Finn specials”—should GHB and unaware consumer,this drug has become a and ketamine be banned? J Am Pharm Assoc 1999; preferred drug of abuse.1–5 39:442–3. 162 JABFP March–April 2002 Vol. 15 No. 2 5. Ingels M,Rangan C,Bellezzo J,Clark RF. Coma H. Verve and Jolt: deadly new Internet drugs. Pedi- and respiratory depression following the ingestion of atrics 2000;106:829–30. GHB and its precursors: three cases. J Emerg Med 12. Friedman J,Westlake R,Furman M. “Grievous J Am Board Fam Pract: first published as on 1 March 2002. Downloaded from 2000; 19:47–50. bodily harm:” gamma-hydroxybutyrate abuse lead- 6. Adverse events associated with ingestion of gamma- ing to a Wernicke- Korsakoff syndrome.
Load more

Recommended publications
  • Drugs Inducing Insomnia As an Adverse Effect
    2 Drugs Inducing Insomnia as an Adverse Effect Ntambwe Malangu University of Limpopo, Medunsa Campus, School of Public Health, South Africa 1. Introduction Insomnia is a symptom, not a stand-alone disease. By definition, insomnia is "difficulty initiating or maintaining sleep, or both" or the perception of poor quality sleep (APA, 1994). As an adverse effect of medicines, it has been documented for several drugs. This chapter describes some drugs whose safety profile includes insomnia. In doing so, it discusses the mechanisms through which drug-induced insomnia occurs, the risk factors associated with its occurrence, and ends with some guidance on strategies to prevent and manage drug- induced insomnia. 2. How drugs induce insomnia There are several mechanisms involved in the induction of insomnia by drugs. Some drugs affects sleep negatively when being used, while others affect sleep and lead to insomnia when they are withdrawn. Drugs belonging to the first category include anticonvulsants, some antidepressants, steroids and central nervous stimulant drugs such amphetamine and caffeine. With regard to caffeine, the mechanism by which caffeine is able to promote wakefulness and insomnia has not been fully elucidated (Lieberman, 1992). However, it seems that, at the levels reached during normal consumption, caffeine exerts its action through antagonism of central adenosine receptors; thereby, it reduces physiologic sleepiness and enhances vigilance (Benington et al., 1993; Walsh et al., 1990; Rosenthal et al., 1991; Bonnet and Arand, 1994; Lorist et al., 1994). In contrast to caffeine, methamphetamine and methylphenidate produce wakefulness by increasing dopaminergic and noradrenergic neurotransmission (Gillman and Goodman, 1985). With regard to withdrawal, it may occur in 40% to 100% of patients treated chronically with benzodiazepines, and can persist for days or weeks following discontinuation.
    [Show full text]
  • THE USE of MIRTAZAPINE AS a HYPNOTIC O Uso Da Mirtazapina Como Hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa
    ARTIGO ESPECIAL THE USE OF MIRTAZAPINE AS A HYPNOTIC O uso da mirtazapina como hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated with known side effects. Antidepressants are associated with various effects on sleep patterns, depending on the intrinsic pharmacological properties of the active agent, such as degree of inhibition of serotonin or noradrenaline reuptake, effects on 5-HT1A and 5-HT2 receptors, action(s) at alpha-adrenoceptors, and/or histamine H1 sites. Mirtazapine is a noradrenergic and specific serotonergic antidepressive agent that acts by antagonizing alpha-2 adrenergic receptors and blocking 5-HT2 and 5-HT3 receptors. It has high affinity for histamine H1 receptors, low affinity for dopaminergic receptors, and lacks anticholinergic activity. In spite of these potential beneficial effects of mirtazapine on sleep, no placebo-controlled randomized clinical trials of ABSTRACT mirtazapine in primary insomniacs have been conducted. Mirtazapine was associated with improvements in sleep on normal sleepers and depressed patients. The most common side effects of mirtazapine, i.e. dry mouth, drowsiness, increased appetite and increased body weight, were mostly mild and transient. Considering its use in elderly people, this paper provides a revision about studies regarding mirtazapine for sleep disorders. KEYWORDS: sleep; antidepressive agents; sleep disorders; treatment� A prescrição de hipnóticos aprovados para insônia diminuiu em mais de 50%, enquanto de antidepressivos ultrapassou a dos primeiros.
    [Show full text]
  • Herbal Remedies and Sleep
    HERBAL REMEDIES AND SLEEP • Some people use herbal remedies to treat sleep problems. They may choose this in preference to sleeping pills. • There have been studies on some of these herbs. However, not all of them have been conducted properly. For some herbs, there is virtually no evidence to show whether they are effective or not. • The most frequently studied herbs are Valerian, Kava, Hops, Chamomile, and Passionflower. However, there is little convincing evidence to suggest that they work well for improving sleep. • Some herbal remedies have been associated with adverse health effects. Note: All words that are underlined relate to topics in the Sleep Health Foundation Information Library at www.sleephealthfoundation.org.au 1. Why try herbs to help your sold by a specific manufacturer for a certain time-period. Trials testing effectiveness are expensive, and without a patent, companies may not sleep? be able to recover their costs through guaranteed sales, even if the herb has potential. However, there have been studies of some herbs About 40% of people use alternative or complementary medicines at used for insomnia and anxiety. Here we focus on herbs where least occasionally, and 4.5% use them to treat sleep problem. Some reasonable information exists from clinical research trials. people who are concerned about using sleeping pills will turn to herbal remedies to help them sleep (see our page on Sleeping Tablets). Melatonin is not a herbal remedy (for more information see Melatonin). 3. What does the evidence say about herbs helping sleep? 2. Has the effectiveness of herbs In the table below, we look at the effectiveness of eight herbal remedies in treating sleep problems as treatments of insomnia.
    [Show full text]
  • Current and Experimental Therapeutics of Insomnia
    133 CURRENT AND EXPERIMENTAL THERAPEUTICS OF INSOMNIA DANIEL J. BUYSSE CYNTHIA M. DORSEY 15% (4,5). Epidemiologic studies point to a consistent set of risk factors for insomnia. These include a previous history INSOMNIA: DEFINITIONS, IMPACT, AND of insomnia, increasing age, female gender, psychiatric DIAGNOSIS symptoms and disorders, medical symptoms and disorders, impaired activities of daily living, anxiolytic and hypnotic Definition of Insomnia Symptoms and medication use, and low socioeconomic status. The increas- Disorders ing prevalence of insomnia with age may be explained in large part by increasing comorbidity with medical and psy- Insomnia can refer to either a symptom or clinical disorder. chiatric disorders and medication use. The incidence of in- The symptom of insomnia is the subjective complaint of somnia also increases with age and is greater in women than difficulty falling or staying asleep, poor quality sleep, or men. On the other hand, remission of insomnia decreases inadequate sleep duration, despite having an adequate op- with age and is less common in women. Together, preva- portunity for sleep. Two points in this definition deserve lence, incidence, and remission data indicate that insomnia specific attention. First, insomnia is a subjective complaint is often a chronic condition. Between 50% and 80% of not currently defined by laboratory test results or a specific individuals with insomnia at baseline have a persistent com- duration of sleep or wakefulness. Second, the insomnia plaint after follow-up intervals of 1 to 3.5 years (1,6–8). symptom occurs despite the individual having adequate op- portunity to sleep. This distinguishes insomnia from sleep deprivation, which has different causes, consequences, and Impact of Insomnia clinical presentations.
    [Show full text]
  • Insomnia in Adults
    New Guideline February 2017 The AASM has published a new clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. These new recommendations are based on a systematic review of the literature on individual drugs commonly used to treat insomnia, and were developed using the GRADE methodology. The recommendations in this guideline define principles of practice that should meet the needs of most adult patients, when pharmacologic treatment of chronic insomnia is indicated. The clinical practice guideline is an essential update to the clinical guideline document: Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349. SPECIAL ARTICLE Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults Sharon Schutte-Rodin, M.D.1; Lauren Broch, Ph.D.2; Daniel Buysse, M.D.3; Cynthia Dorsey, Ph.D.4; Michael Sateia, M.D.5 1Penn Sleep Centers, Philadelphia, PA; 2Good Samaritan Hospital, Suffern, NY; 3UPMC Sleep Medicine Center, Pittsburgh, PA; 4SleepHealth Centers, Bedford, MA; 5Dartmouth-Hitchcock Medical Center, Lebanon, NH Insomnia is the most prevalent sleep disorder in the general popula- and disease management of chronic adult insomnia, using existing tion, and is commonly encountered in medical practices. Insomnia is evidence-based insomnia practice parameters where available, and defined as the subjective perception of difficulty with sleep initiation, consensus-based recommendations to bridge areas where such pa- duration, consolidation, or quality that occurs despite adequate oppor- rameters do not exist.
    [Show full text]
  • Herbs a T a Glance: Valerian
    Valerian This fact sheet provides basic information about the herb valerian—common names, uses, potential side effects, and resources for more information. Valerian is a plant native to Europe and Asia; it is also found in North America. Valerian has been used as a medicinal herb since at least the time of ancient Greece and Rome. Its therapeutic uses were described by Hippocrates, and in the 2nd century, Galen prescribed valerian for insomnia. Common Names—valerian, all-heal, garden heliotrope Latin Name—Valeriana officinalis What It Is Used For • Valerian has long been used for sleep disorders and anxiety. • Valerian has also been used for other conditions, such as headaches, depression, irregular heartbeat, and trembling. How It Is Used The roots and rhizomes (underground stems) of valerian are typically used to make supplements, including capsules, tablets, and liquid extracts, as well as teas. What the Science Says • Research suggests that valerian may be helpful for insomnia, but there is not enough evidence from well-designed studies to confirm this. • There is not enough scientific evidence to determine whether valerian works for anxiety or for other conditions, such as depression and headaches. • Recent NCCAM-funded research on valerian includes studies on the herb’s effects on sleep in healthy older adults and in people with Parkinson’s disease. Side Effects and Cautions • Studies suggest that valerian is generally safe to use for short periods of time (for example, 4 to 6 weeks). • No information is available about the long-term safety of valerian. • Valerian can cause mild side effects, such as headaches, dizziness, upset stomach, and tiredness the morning after its use.
    [Show full text]
  • Insomnia-1111 30/11/11 4:37 PM Page 1
    SHF-Insomnia-1111 30/11/11 4:37 PM Page 1 Insomnia Important Things to Know About Insomnia • Around 1 in 3 people have at least mild insomnia. • Many poor sleepers have developed poor sleep habits. • For specialist help, cognitive behavioural therapy for insomnia is best • In the long run, taking sleeping pills isn’t effective. • There are sleep specialists, clinics and on-line programs that can help. What is insomnia? How common is insomnia? Insomnia is said to be present when you regularly find it Most people have experience insomnia symptoms at hard to fall asleep or stay asleep. It has several patterns. some time of their lives. At any given time around 10% You may have trouble getting to sleep initially. Or even if of people have at least mild insomnia. you can fall asleep, you might not be able to stay asleep for as long as you would like. Also you may wake up Who is at risk? during the night and not be able to go back to sleep for a long time. Many people have two of the above problems, Older people with poor health have a higher risk. Also or even all three. Because of these, you might feel tired women have twice the rates compared to men. This may during the day. be related to higher rates of anxiety and depression, which can be associated with insomnia. Shift workers What causes insomnia? have a higher risk too. Insomnia has many causes which can include: How does it affect people? • Some medicines and drugs, e.g.
    [Show full text]
  • Valerian SUSAN HADLEY, M.D., Middlesex Hospital, Middletown, Connecticut JUDITH J
    COMPLEMENTARY AND ALTERNATIVE MEDICINE Valerian SUSAN HADLEY, M.D., Middlesex Hospital, Middletown, Connecticut JUDITH J. PETRY, M.D., Vermont Healing Tools Project, Brattleboro, Vermont Valerian is a traditional herbal sleep remedy that has been studied with a variety of methodologic designs using multiple dosages and preparations. Research has focused on subjective evaluations of sleep patterns, particularly sleep latency, and study populations have primarily consisted of self-described poor sleepers. Valerian improves subjective experiences of sleep when taken nightly over one- to two-week periods, and it appears to be a safe sedative/hypnotic choice in patients with mild to moderate insomnia. The evi- dence for single-dose effect is contradictory. Valerian is also used in patients with mild anxiety, but the data supporting this indication are limited. Although the adverse effect profile and tolerability of this herb are excellent, long-term safety studies are lacking. (Am Fam Physician 2003;67:1755-8. Copyright©2003 American Academy of Family Physicians) he root of valerian, a perennial triates, valeric acid) and interaction with neu- herb native to North America, rotransmitters such as GABA (valeric acid and Asia, and Europe, is used most unknown fractions).2,3 commonly for its sedative and hypnotic properties in patients Uses and Efficacy Twith insomnia, and less commonly as an SEDATIVE/HYPNOTIC anxiolytic. Multiple preparations are available, Several clinical studies have shown that and the herb is commonly combined with valerian is effective in the treatment of insom- other herbal medications. This review nia, most often by reducing sleep latency. A addresses only studies that used valerian root double-blind, placebo-controlled trial4 com- as an isolated herb.
    [Show full text]
  • Management of Hypnotics in Patients with Insomnia and Heart Failure During Hospitalization: a Systematic Review
    Review Management of Hypnotics in Patients with Insomnia and Heart Failure during Hospitalization: A Systematic Review Pablo Jorge-Samitier 1,2 , María Teresa Fernández-Rodrigo 2,* , Raúl Juárez-Vela 3 , Isabel Antón-Solanas 2,4,* and Vicente Gea-Caballero 5 1 Hospital Clínico Lozano Blesa, Avenida San Juan Bosco, 15, 50009 Zaragoza, Spain; [email protected] 2 Department of Physiatry and Nursing, Faculty of Health Sciences, University of Zaragoza, C/Domingo Miral s/n, 50009 Zaragoza, Spain 3 Faculty of Medicine, University of Salamanca, Avenida Alfonso X El Sabio SN, 37008 Salamanca, Spain; [email protected] 4 Research Group GENIAPA (GIIS094), Institute of Research of Aragon, Avenida San Juan Bosco, 13, 50009 Zaragoza, Spain 5 Nursing School La Fe, Adscript Center of the University of Valencia, Research Group GREIACC, Health Research Institute La Fe, 46026 Valencia, Spain; [email protected] * Correspondence: [email protected] (M.T.F.-R.); [email protected] (I.A.-S.) Abstract: Background: Heart failure is a chronic, progressive syndrome of signs and symptoms, which has been associated to a range of comorbidities including insomnia. Acute decompensa- tion of heart failure frequently leads to hospital admission. During hospital admission, long-term pharmacological treatments such as hypnotics can be modified or stopped. Aim: To synthesize the scientific evidence available about the effect of withdrawing hypnotic drugs during hospital Citation: Jorge-Samitier, P.; admission in patients with decompensated heart failure and insomnia. Method: A systematic review Fernández-Rodrigo, M.T.; Juárez-Vela, of the literature following the Preferred Reporting Items for Systematic reviews and Meta-Analyses R.; Antón-Solanas, I.; Gea-Caballero, (PRISMA) guidelines was carried out in the following scientific databases: PubMed, Scopus, Dialnet V.
    [Show full text]
  • Doxepin (Silenor) for Insomnia DHIREN PATEL, Pharmd, and JENNIFER D
    STEPS New Drug Reviews Doxepin (Silenor) for Insomnia DHIREN PATEL, PharmD, and JENNIFER D. GOLDMAN-LEVINE, PharmD Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts STEPS new drug reviews Silenor is a new low-dose formulation of the tricyclic antidepressant doxepin (which is typi- cover Safety, Tolerability, cally taken as a 25- to 150-mg dose at bedtime). Low-dose doxepin is labeled for the treatment Effectiveness, Price, and Simplicity. Each indepen- of insomnia characterized by difficulty maintaining sleep. The exact mechanism by which the dent review is provided medication exerts its sleep maintenance effect is unknown, but is thought to be antagonism 1 by authors who have no of histamine H1 receptors. financial association with the drug manufacturer. The series coordinator for Drug Dosage Dose form Monthly cost* AFP is Allen F. Shaugh- nessy, PharmD, Tufts Doxepin (Silenor) 3 to 6 mg daily 3-mg and 6-mg tablets $208 University Family Medicine Residency Program at *—Price for 30 3-mg or 6-mg tablets at CVS Pharmacy on May 18, 2011. Cambridge Health Alli- ance, Malden, Mass. A collection of STEPS pub- lished in AFP is available SAFETY of 1,017 patients, approximately 1 percent at http://www.aafp.org/ 1 afp/steps. Doxepin is safe when used at low dosages. withdrew because of adverse effects. Rebound Antidepressants are required to have label- insomnia and withdrawal symptoms have not ing that warns of an increased risk of sui- been reported. Next-day sedation, anticholin- cide; however, there have been no reports ergic effects, and memory impairment do not of suicide among patients taking low-dose occur at low dosages.2,3 The use of central ner- doxepin.
    [Show full text]
  • Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: an American Academy of Sleep Medicine Clinical Practice Guideline Michael J
    pii: jc-00382-16 http://dx.doi.org/10.5664/jcsm.6470 SPECIAL ARTICLES Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline Michael J. Sateia, MD1; Daniel J. Buysse, MD2; Andrew D. Krystal, MD, MS3; David N. Neubauer, MD4; Jonathan L. Heald, MA5 1Geisel School of Medicine at Dartmouth, Hanover, NH; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of California, San Francisco, San Francisco, CA; 4Johns Hopkins University School of Medicine, Baltimore, MD; 5American Academy of Sleep Medicine, Darien, IL Introduction: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences.
    [Show full text]
  • Safe Prescribing of Benzodiazepines for Anxiety and Insomina
    Updated: Oct. 18, 2016 [Type here] Prescribing Guidelines for Pennsylvania SAFE PRESCRIBING OF BENZODIAZEPINES FOR ANXIETY AND INSOMINA Anxiety is commonly encountered in clinical benzodiazepine substance use disorder. The risk of practice, either as an acute isolated symptom dependence increases with dose and duration of associated with major life events or comorbid with therapy. another condition, e.g., depression. Anxiety may also be the core symptom of a psychiatric disorder, While anxiety disorders are amenable to short-term including panic disorder, phobias and generalized treatment with benzodiazepines, they are not first- anxiety disorder. The prevalence of anxiety line treatments for anxiety disorders and are not disorders in the U.S. is approximately 4 percent. effective for the long-term treatment of these disorders. Rather, there are other much more Though benzodiazepines are effective in the short- effective treatment options, including evidence- term treatment of severe anxiety and panic disorders, based psychotherapies, e.g., cognitive behavioral evidence shows that continuing them beyond four to therapy (CBT), other non-pharmacological six weeks will likely result in loss of efficacy and the interventions, and medication management using development of tolerance and dependence and, serotonin-specific reuptake inhibitors (SSRIs) or consequently, increase the risk of development of a ©2015 Brought to you by the Commonwealth of Pennsylvania Benzodiazepines for Anxiety and Insomnia | 2 serotonin-norepinephrine reuptake inhibitors, types of medications found to be present in deaths (SNRIs). associated with opioid use. Similarly, insomnia, either as a symptom of another It is therefore imperative that physicians and other disorder, or as the core symptom of a sleep disorder, prescribers approach the prescribing of may have a lifetime prevalence as high as 40 percent.
    [Show full text]